The Power of Prevention: The Untapped Potential of Adult Immunisation Programmes

By HEOR Staff Writer

January 1, 2024

The Unseen Value of Adult Immunisation

Adult immunisation programmes are often overlooked. But these are critical to addressing key health and societal challenges. A detailed review by the  Office of Health Economics (OHE) of these programmes has recently been conducted. Focusing on diseases such as seasonal influenza, pneumococcal disease, herpes zoster, and respiratory syncytial virus, reveals their crucial role in global health. The benefits of these programmes extend beyond health, impacting social care systems and aligning with global agendas such as the UN Sustainable Development Goals (SDGs) and the WHO Immunisation Agenda 2030 (IA2030). However, the full value of such programmes is often underestimated due to underrepresentation in academic literature, leading to suboptimal investment decisions.

The Rising Burden of Infectious Diseases and Ageing Populations

The world is witnessing significant demographic shifts, with ageing populations becoming a dominant trend. Infectious diseases like shingles and pneumococcal disease pose severe threats to older adults, leading to substantial hospitalisation burdens. Alongside this, the ‘tripledemic’ of COVID-19, seasonal influenza, and RSV, coupled with rising rates of chronic diseases among younger age groups, is exerting immense pressure on healthcare systems. This necessitates a shift from treatment to prevention, with vaccination standing as a fundamental preventive measure.

The Economic and Health Benefits of Adult Immunisation

Adult immunisation programmes are not just health measures, but also economically beneficial strategies. They are cost-effective and can result in net cost savings for healthcare systems. Recent studies in Australia and Germany underline that these programmes offer financial gains by averting hospital inpatient and emergency care. Expanding adult immunisation programmes and coverage can lead to substantial productivity gains and economic benefits for society. Moreover, these programmes can contribute to health and economic equity within countries, benefiting vulnerable and underserved communities.

The Urgent Need for Further Research and Adoption of a Preventive Mindset

Despite the clear benefits, significant gaps exist in evidence regarding the broader elements of the value of immunisation programmes. This calls for urgent research to prioritise and enhance adult immunisation programmes for the benefit of society and public health. It is vital for policy- and decision-makers to adopt a prevention-first mindset and implement robust adult immunisation programmes that are proven cost-effective. Expanding the evidence base for the broader value of adult immunisation is a crucial step towards optimising the value of these programmes.

Conclusion: The Power of Prevention

Adult immunisation programmes are powerful tools in the fight against infectious diseases and the burden they place on healthcare systems. They are cost-effective, promote health equity, and align with global health goals. However, their full potential remains untapped, largely due to underrepresentation in academic literature and a lack of awareness among decision-makers. It’s time to shift our focus from treatment to prevention and recognise the immense value that adult immunisation programmes bring to society.

Reference url

Recent Posts

EMA CHMP Meeting Highlights
Regulatory Insights from EMA CHMP Meeting Highlights

By HEOR Staff Writer

June 26, 2026

The EMA CHMP Meeting Highlights from 22-25 June 2026 show the committee advancing six new medicines while maintaining rigorous evidentiary standards for complex and rare conditions. Positive opinions covered an inactivated influenza vaccine for adults 50 and older, a levodopa-carbidopa intestinal...
KEYTRUDA combination therapy
KEYTRUDA Combination Therapy Gains FDA Approval for Advanced Triple-Negative Breast Cancer

By João L. Carapinha

June 26, 2026

The FDA has approved KEYTRUDA combination therapy with Trodelvy as first-line treatment for adults with unresectable locally advanced or metastatic triple-negative breast cancer whose tumors express PD-L1 at a Combined Positive Score of 10 or greater. This marks the first regulatory nod for a PD-...
calcified carotid lesion preparation
Innovations in Calcified Carotid Lesion Preparation for Enhanced Stroke Management

By João L. Carapinha

June 26, 2026

Johnson & Johnson has begun enrolling patients in the SKYWARD clinical program, advancing calcified carotid lesion preparation with a purpose-built intravascular lithotripsy platform that fractures hardened plaque to improve stent deployment. This first-of-its-kind